Figure 1

Estrogen receptor β expression decreases Akt signaling in breast cancer cells. (A) T47-DERβ cells were treated for 1 day up to 7 days with 10 ng/mL (-ERβ) or 0.01 ng/mL (+ERβ) doxycycline in the presence or absence of 10 nM 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN). (B) MCF-7ERβ cells were treated for 4 days or 7 days with 10 ng/mL (-ERβ) or 0.01 ng/mL (+ERβ) doxycycline in the presence or absence of 10 nM DPN. (C) T47-DPBI control cells were treated for 4 days with 10 ng/mL or 0.01 ng/mL doxycycline, in the presence or absence of 10 nM DPN. (D and E) T47-DERβ cells were treated for 4 days with 10 ng/mL (-ERβ) or 0.01 ng/mL (+ERβ) doxycycline in the presence or absence of (D) 10 nM DPN with or without 100 nM ICI 182, 789 (ICI) or (E) 100 nM 4-hydroxy-tamoxifen (4-OH-T). For Figures 1A to 1E, cell lysates were analyzed by immunoblotting. In Figure 1A, the estrogen receptor β (ERβ) antibody used was 14021 from Abcam. In Figures 1B, 1D and 1E, the ERβ antibody was GTX110607 from GeneTex. This antibody produced a nonspecific band above the ERβ band.